Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome
- PMID: 19877054
- DOI: 10.1002/art.24903
Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome
Abstract
Objective: To assess the effect of rituximab (anti-CD20 antibody) therapy on the (immuno)histopathology of parotid tissue in patients with primary Sjögren's syndrome (SS) and the correlation of histologic findings with the flow rate and composition of parotid saliva.
Methods: In a phase II study, an incisional parotid biopsy specimen was obtained from 5 patients with primary SS before and 12 weeks after rituximab treatment (4 infusions of 375 mg/m(2)). The relative amount of parotid parenchyma, lymphocytic infiltrate, and fat, and the presence/quantity of germinal centers and lymphoepithelial duct lesions were evaluated. Immunohistochemical characterization was performed to analyze the B:T cell ratio of the lymphocytic infiltrate (CD20, CD79a, CD3) and cellular proliferation in the acinar parenchyma (by double immunohistologic labeling for cytokeratin 14 and Ki-67). Histologic data were assessed for correlations with the parotid flow rate and saliva composition.
Results: Four patients showed an increased salivary flow rate and normalization of the initially increased salivary sodium concentration. Following rituximab treatment, the lymphocytic infiltrate was reduced, with a decreased B:T cell ratio and (partial) disappearance of germinal centers. The amount and extent of lymphoepithelial lesions decreased in 3 patients and was completely absent in 2 patients. The initially increased proliferation of acinar parenchyma in response to inflammation was reduced in all patients.
Conclusion: Sequential parotid biopsy specimens obtained from patients with primary SS before and after rituximab treatment demonstrated histopathologic evidence of reduced glandular inflammation and redifferentiation of lymphoepithelial duct lesions to regular striated ducts as a putative morphologic correlate of increased parotid flow and normalization of the salivary sodium content. These histopathologic findings in a few patients underline the efficacy of B cell depletion and indicate the potential for glandular restoration in SS.
Similar articles
-
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.Arthritis Rheum. 2005 Sep;52(9):2740-50. doi: 10.1002/art.21260. Arthritis Rheum. 2005. PMID: 16142737 Clinical Trial.
-
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.Arthritis Rheum. 2010 Apr;62(4):960-8. doi: 10.1002/art.27314. Arthritis Rheum. 2010. PMID: 20131246 Clinical Trial.
-
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.Arthritis Rheum. 2007 May;56(5):1464-77. doi: 10.1002/art.22603. Arthritis Rheum. 2007. PMID: 17469105 Clinical Trial.
-
Salivary gland biopsy for Sjögren's syndrome.Oral Maxillofac Surg Clin North Am. 2014 Feb;26(1):23-33. doi: 10.1016/j.coms.2013.09.005. Oral Maxillofac Surg Clin North Am. 2014. PMID: 24287191 Review.
-
Salivary histopathology in diagnosis of Sjögren's syndrome.Scand J Rheumatol Suppl. 1986;61:36-43. Scand J Rheumatol Suppl. 1986. PMID: 3296156 Review.
Cited by
-
[Pattern recognition in the differential diagnosis of salivary lymphoepithelial lesions].Pathologe. 2009 Nov;30(6):432-41. doi: 10.1007/s00292-009-1203-7. Pathologe. 2009. PMID: 19813014 German.
-
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?Arthritis Res Ther. 2011 Feb 28;13(1):205. doi: 10.1186/ar3234. Arthritis Res Ther. 2011. PMID: 21371351 Free PMC article. Review.
-
Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jun;111(6):673-80. doi: 10.1016/j.tripleo.2011.01.040. Epub 2011 Apr 16. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011. PMID: 21497524 Free PMC article.
-
Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.Trials. 2022 Nov 12;23(1):939. doi: 10.1186/s13063-022-06874-w. Trials. 2022. PMID: 36371234 Free PMC article.
-
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.BMJ Open. 2019 Mar 20;9(3):e025687. doi: 10.1136/bmjopen-2018-025687. BMJ Open. 2019. PMID: 30898822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous